Nuvation Bio [NUVB] vs Alnylam [ALNY] Detailed Stock Comparison
Nuvation Bio
NYSE
Loading...
Alnylam
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 18 vital metrics comparison: Nuvation Bio wins in 6 metrics, Alnylam wins in 12 metrics, with 0 ties. Alnylam appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Nuvation Bio | Alnylam | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.49 | -213.71 | Alnylam |
| Price-to-Book Ratio | 2.88 | 244.95 | Nuvation Bio |
| Debt-to-Equity Ratio | 15.49 | 1,093.31 | Nuvation Bio |
| PEG Ratio | 0.02 | -384.08 | Alnylam |
| EV/EBITDA | 2.61 | -496.41 | Alnylam |
| Profit Margin (TTM) | 10.10% | -12.96% | Nuvation Bio |
| Operating Margin (TTM) | -1,315.72% | -2.09% | Alnylam |
| Return on Equity | -44.84% | -257.83% | Nuvation Bio |
| Return on Assets (TTM) | 20.17% | -2.63% | Nuvation Bio |
| Free Cash Flow (TTM) | $-130.58M | $-42.59M | Alnylam |
| 1-Year Return | 2.95% | 75.61% | Alnylam |
| Price-to-Sales Ratio (TTM) | 74.87 | 24.95 | Alnylam |
| Enterprise Value | $524.78M | $61.40B | Alnylam |
| EV/Revenue Ratio | 36.56 | 24.94 | Alnylam |
| Gross Profit Margin (TTM) | 46.70% | 81.52% | Alnylam |
| Revenue per Share (TTM) | $0 | $19 | Alnylam |
| Earnings per Share (Diluted) | $-0.38 | $-2.49 | Nuvation Bio |
| Beta (Stock Volatility) | 1.37 | 0.32 | Alnylam |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Nuvation Bio vs Alnylam Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Nuvation Bio | -6.27% | -19.49% | 35.34% | 73.48% | 40.18% | 21.24% |
| Alnylam | -0.57% | 3.07% | 8.36% | 52.92% | 92.18% | 99.42% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Nuvation Bio | 2.95% | 38.33% | -71.45% | -68.44% | -68.44% | -68.44% |
| Alnylam | 75.61% | 118.70% | 252.21% | 331.92% | 3,117.06% | 3,386.75% |
News Based Sentiment: Nuvation Bio vs Alnylam
Nuvation Bio
News based Sentiment: POSITIVE
Nuvation Bio demonstrated strong early commercial traction with IBTROZI™ in Q2 2025, coupled with active investor engagement and a potential financing deal for taletrectinib. While some analyst concerns exist, the overall narrative is positive, supported by insider buying and bullish market signals.
Alnylam
News based Sentiment: POSITIVE
September was a remarkably positive month for Alnylam, driven by the successful launch of Ambutra, strong financial results, and positive analyst revisions. The company's transition to profitability and proactive financial planning further strengthen its investment case, indicating a solid growth trajectory and increasing investor confidence.
Performance & Financial Health Analysis: Nuvation Bio vs Alnylam
| Metric | NUVB | ALNY |
|---|---|---|
| Market Information | ||
| Market Cap | $1.07B | $61.07B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 8,443,260 | 1,215,328 |
| 90 Day Avg. Volume | 6,001,997 | 1,321,166 |
| Last Close | $3.14 | $465.89 |
| 52 Week Range | $1.54 - $4.09 | $205.87 - $484.21 |
| % from 52W High | -23.23% | -3.78% |
| All-Time High | $15.23 (May 24, 2021) | $484.21 (Sep 09, 2025) |
| % from All-Time High | -79.38% | -3.78% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 2.37% | 0.17% |
| Quarterly Earnings Growth | 2.37% | 0.17% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | -0.13% |
| Operating Margin (TTM) | -13.16% | -0.02% |
| Return on Equity (TTM) | -0.45% | -2.58% |
| Debt to Equity (MRQ) | 15.49 | 1,093.31 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.09 | $1.91 |
| Cash per Share (MRQ) | $1.78 | $21.80 |
| Operating Cash Flow (TTM) | $-168,192,000 | $-15,539,000 |
| Levered Free Cash Flow (TTM) | $179.17M | $85.71M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Nuvation Bio vs Alnylam
| Metric | NUVB | ALNY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.49 | -213.71 |
| Forward P/E | -4.98 | -384.08 |
| PEG Ratio | 0.02 | -384.08 |
| Price to Sales (TTM) | 74.87 | 24.95 |
| Price to Book (MRQ) | 2.88 | 244.95 |
| Market Capitalization | ||
| Market Capitalization | $1.07B | $61.07B |
| Enterprise Value | $524.78M | $61.40B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 36.56 | 24.94 |
| Enterprise to EBITDA | 2.61 | -496.41 |
| Risk & Other Metrics | ||
| Beta | 1.37 | 0.32 |
| Book Value per Share (MRQ) | $1.09 | $1.91 |
Financial Statements Comparison: Nuvation Bio vs Alnylam
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | NUVB | ALNY |
|---|---|---|
| Revenue/Sales | $4.83M | $773.69M |
| Cost of Goods Sold | $2.58M | $142.95M |
| Gross Profit | $2.26M | $630.74M |
| Research & Development | $27.36M | $323.62M |
| Operating Income (EBIT) | $-63.59M | $-16.20M |
| EBITDA | $-58.65M | $35.44M |
| Pre-Tax Income | $-59.01M | $-35.36M |
| Income Tax | $0 | $30.92M |
| Net Income (Profit) | $-59.01M | $-66.28M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | NUVB | ALNY |
|---|---|---|
| Cash & Equivalents | $47.98M | $1.02B |
| Total Current Assets | $475.57M | $3.27B |
| Total Current Liabilities | $52.77M | $1.08B |
| Long-Term Debt | $3.84M | $1.26B |
| Total Shareholders Equity | $419.46M | $115.44M |
| Retained Earnings | $-963.98M | $-7.35B |
| Property, Plant & Equipment | $1.53M | $695.92M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | NUVB | ALNY |
|---|---|---|
| Operating Cash Flow | $-32.06M | $-145.39M |
| Capital Expenditures | $-72,000 | $-8.97M |
| Free Cash Flow | $-42.70M | $-127.28M |
| Debt Repayment | $-534,000 | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | NUVB | ALNY |
|---|---|---|
| Shares Short | 68.13M | 3.97M |
| Short Ratio | 15.08 | 2.99 |
| Short % of Float | 0.32% | 0.04% |
| Average Daily Volume (10 Day) | 8,443,260 | 1,215,328 |
| Average Daily Volume (90 Day) | 6,001,997 | 1,321,166 |
| Shares Outstanding | 337.84M | 129.29M |
| Float Shares | 231.05M | 126.15M |
| % Held by Insiders | 0.19% | 0.04% |
| % Held by Institutions | 0.67% | 0.99% |
Dividend Analysis & Yield Comparison: Nuvation Bio vs Alnylam
| Metric | NUVB | ALNY |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |